Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

2.

Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.

Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK.

J Pharmacol Exp Ther. 1994 Sep;270(3):1000-7.

PMID:
7932147
3.

Meige syndrome in the spectrum of Lewy body disease.

Mark MH, Sage JI, Dickson DW, Heikkila RE, Manzino L, Schwarz KO, Duvoisin RC.

Neurology. 1994 Aug;44(8):1432-6.

PMID:
8058144
4.

Biochemical mechanisms underlying MPTP-induced and idiopathic parkinsonism. New vistas.

Singer TP, Ramsay RR, Sonsalla PK, Nicklas WJ, Heikkila RE.

Adv Neurol. 1993;60:300-5. Review. No abstract available.

PMID:
8380523
5.

In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72,974A and fluorodeprenyl.

Terleckyj IA, Heikkila RE.

Ann N Y Acad Sci. 1992 May 11;648:365-7. No abstract available.

PMID:
1637071
6.

Mitochondrial mechanisms of neurotoxicity.

Nicklas WJ, Saporito M, Basma A, Geller HM, Heikkila RE.

Ann N Y Acad Sci. 1992 May 11;648:28-36. Review. No abstract available.

PMID:
1637057
7.

1-Methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells is enhanced by preventing glycolysis.

Basma AN, Heikkila RE, Saporito MS, Philbert M, Geller HM, Nicklas WJ.

J Neurochem. 1992 Mar;58(3):1052-9.

PMID:
1737983
8.

The MPTP-treated mouse as a model of parkinsonism: how good is it?

Heikkila RE, Sonsalla PK.

Neurochem Int. 1992 Mar;20 Suppl:299S-303S. Review. No abstract available.

PMID:
1365446
9.
11.
12.
13.

4'-alkylated analogs of 1-methyl-4-phenylpyridinium ion are potent inhibitors of mitochondrial respiration.

Youngster SK, Gluck MR, Heikkila RE, Nicklas WJ.

Biochem Biophys Res Commun. 1990 Jun 15;169(2):758-64.

PMID:
2357232
14.

Potentiation by the tetraphenylboron anion of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its pyridinium metabolite.

Heikkila RE, Hwang J, Ofori S, Geller HM, Nicklas WJ.

J Neurochem. 1990 Mar;54(3):743-50.

PMID:
2303810
15.

Steady plasma levodopa concentrations required for good clinical response to CR-4 in patients with 'on-off'.

McHale DM, Sage JI, Sonsalla PK, Heikkila RE, Duvoisin RC.

Eur Neurol. 1990;30(2):90-2.

PMID:
2340841
16.

Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP.

Heikkila RE, Terleckyj I, Sieber BA.

J Neural Transm Suppl. 1990;32:217-27.

PMID:
2128498
17.

Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson's disease.

Sage JI, Sonsalla PK, McHale DM, Heikkila RE, Duvoisin RC.

Adv Neurol. 1990;53:383-6. No abstract available.

PMID:
2122646
18.
19.

Structural dependence of the inhibition of mitochondrial respiration and of NADH oxidase by 1-methyl-4-phenylpyridinium (MPP+) analogs and their energized accumulation by mitochondria.

Ramsay RR, Youngster SK, Nicklas WJ, McKeown KA, Jin YZ, Heikkila RE, Singer TP.

Proc Natl Acad Sci U S A. 1989 Dec;86(23):9168-72.

20.

Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson's disease.

Sage JI, Trooskin S, Sonsalla PK, Heikkila RE.

Neurology. 1989 Nov;39(11 Suppl 2):60-3; discussion 72-3.

PMID:
2586763
22.

1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'CH3-MPTP)-induced degeneration of mesostriatal dopaminergic neurons in the mouse: biochemical and neuroanatomical studies.

Manaye KF, Sonsalla PK, Barnett G, Heikkila RE, Woodward DJ, Smith WK, German DC.

Brain Res. 1989 Jul 10;491(2):307-15.

PMID:
2765888
23.

Continuous levodopa infusions to treat complex dystonia in Parkinson's disease.

Sage JI, McHale DM, Sonsalla P, Vitagliano D, Heikkila RE.

Neurology. 1989 Jul;39(7):888-91.

PMID:
2472582
25.
26.

Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.

Heikkila RE, Sieber BA, Manzino L, Sonsalla PK.

Mol Chem Neuropathol. 1989 Jun;10(3):171-83. Review. No abstract available.

PMID:
2669769
27.

Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity.

Sonsalla PK, Nicklas WJ, Heikkila RE.

Science. 1989 Jan 20;243(4889):398-400.

PMID:
2563176
29.

Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Heikkila RE, Kindt MV, Sonsalla PK, Giovanni A, Youngster SK, McKeown KA, Singer TP.

Proc Natl Acad Sci U S A. 1988 Aug;85(16):6172-6.

30.

Isolated jejunal pouches for levodopa delivery in parkinsonian patients with "on-off". Successful experimental model in dogs.

Sage JI, Trooskin S, Schuh L, Duncsak P, Sonsalla PK, Heikkila RE, Manzino L, Reddell M, Duvoisin RC.

Clin Neuropharmacol. 1988 Jun;11(3):212-20.

PMID:
3401857
31.

Studies with the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogs.

Heikkila RE, Youngster SK, Panek DU, Giovanni A, Sonsalla PK.

Toxicology. 1988 May;49(2-3):493-501.

PMID:
3259742
32.

Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.

Kindt MV, Youngster SK, Sonsalla PK, Duvoisin RC, Heikkila RE.

Eur J Pharmacol. 1988 Feb 9;146(2-3):313-8.

PMID:
3131149
33.

Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease.

Sage JI, Schuh L, Heikkila RE, Duvoisin RC.

Clin Neuropharmacol. 1988 Feb;11(1):36-44.

PMID:
3349496
34.

Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice.

Sonsalla PK, Heikkila RE.

Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):345-54.

PMID:
3260386
35.

Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.

Fuller RW, Hemrick-Luecke SK, Kindt MV, Heikkila RE.

Life Sci. 1988;42(3):263-71.

PMID:
3121972
36.

Mitochondrial and metabolic toxicity of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine.

Kindt MV, Heikkila RE, Nicklas WJ.

J Pharmacol Exp Ther. 1987 Sep;242(3):858-63.

PMID:
3498818
37.

Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse.

Sonsalla PK, Youngster SK, Kindt MV, Heikkila RE.

J Pharmacol Exp Ther. 1987 Sep;242(3):850-7.

PMID:
2888874
38.

1-Methyl-4-cyclohexyl-1,2,3,6-tetrahydropyridine (MCTP): an alicyclic MPTP-like neurotoxin.

Youngster SK, Saari WS, Heikkila RE.

Neurosci Lett. 1987 Aug 18;79(1-2):151-6.

PMID:
3499585
39.

The use of the MPTP-treated mouse as an animal model of parkinsonism.

Heikkila RE, Sonsalla PK.

Can J Neurol Sci. 1987 Aug;14(3 Suppl):436-40.

PMID:
3499967
40.
41.

MPTP, MPP+ and mitochondrial function.

Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE.

Life Sci. 1987 Feb 23;40(8):721-9.

PMID:
3100899
42.

Ascorbic acid, redox cycling, lipid peroxidation, and the binding of dopamine receptor antagonists.

Heikkila RE, Manzino L.

Ann N Y Acad Sci. 1987;498:63-76. No abstract available.

PMID:
3476003
43.

Studies on the mechanism of the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Heikkila RE, Nicklas WJ, Duvoisin RC.

Adv Neurol. 1987;45:149-52. No abstract available.

PMID:
3103384
44.
45.

The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.

Sonsalla PK, Heikkila RE.

Eur J Pharmacol. 1986 Oct 7;129(3):339-45.

PMID:
3490988
49.

1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice.

Youngster SK, Duvoisin RC, Hess A, Sonsalla PK, Kindt MV, Heikkila RE.

Eur J Pharmacol. 1986 Mar 18;122(2):283-7.

PMID:
3486770

Supplemental Content

Loading ...
Support Center